Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 5, 2006, Pages 552-559

  Marty, Francisco M ^a,b,c   Lowry, Colleen M ^a   Cutler, Corey S ^a,b,c   Campbell, Bonnie J ^a   Fiumara, Karen ^a   Baden, Lindsey R ^a,b,c   Antin, Joseph H ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aspergillosis; Fungal infection; Sirolimus; Transplantation; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; CYCLOSPORIN; FOSCARNET; IODINATED CONTRAST MEDIUM; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BRADYCARDIA; BRONCHOPNEUMONIA; CATHETER INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEPATORENAL SYNDROME; HUMAN; LEUKOENCEPHALOPATHY; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; MAINTENANCE DRUG DOSE; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; QT PROLONGATION; SEPSIS; SUBARACHNOID HEMORRHAGE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INFECTION;

ADULT; ANTIFUNGAL AGENTS; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INTERACTIONS; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LEUKEMIA; LIPIDS; MALE; MIDDLE AGED; MYCOSES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PYRIMIDINES; RETROSPECTIVE STUDIES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 33745458509     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.12.032     Document Type: Article

References (26)

1. Cutler C., and Antin J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 471-476
2. MacDonald A.S. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 35 3 suppl (2003) 201S-208S
3. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 (2003) 1601-1605
4. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 328-336
5. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. a cohort study. Blood 102 (2003) 2768-2776
6. Singh N., and Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18 (2005) 44-69
7. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
8. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
9. Center for Drug Evaluation and Research, Food and Drug Administration. NDA 21-266 and 21-267, Vfend™{combining enclosing circle} (voriconazole) (2002). http://www.fda.gov/cder/foi/appletter/2002/21266ltr.pdf May 24. Available at: http://www.fda.gov/cder/foi/appletter/2002/21266ltr.pdf. Accessed August 21, 2005
10. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
11. Product Information. Vfend(R), Voriconazole (2005), Pfizer Inc, New York
12. Abel S., Allan R., and Fielding A. Effect of voriconazole on the pharmacokinetics of sirolimus (poster). 12th European Congress of Clinical Microbiology and Infectious Diseases (2002) April 24-27, Milan, Italy
13. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants. an international consensus. Clin Infect Dis 34 (2002) 7-14
14. Ho V.T., Cutler C., Carter S., et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary. thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 571-575
15. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 551-557
16. Mathis A.S., Shah N.K., and Friedman G.S. Combined use of sirolimus and voriconazole in renal transplantation. a report of two cases. Transplant Proc 36 (2004) 2708-2709
17. Garrean S., Massad M.G., Tshibaka M., Hanhan Z., Caines A.E., and Benedetti E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 19 (2005) 698-703
18. Morelon E., Stern M., Israel-Biet D., et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72 (2001) 787-790
19. Morelon E., Stern M., and Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343 (2000) 225-226
20. Singer S.J., Tiernan R., and Sullivan E.J. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343 (2000) 1815-1816
21. Vlahakis N.E., Rickman O.B., and Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 79 (2004) 541-545
22. Tintillier M., Kirch L., Goffin E., Cuvelier C., and Pochet J.M. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 20 (2005) 664-665
23. Venkataramanan R., Zang S., Gayowski T., and Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 46 (2002) 3091-3093
24. Piscitelli S.C., and Rodvold K. Drug Interactions in Infectious Diseases. 2nd ed. (2005), Humana Press, Totowa, NJ
25. Yasuda K., Lan L.B., Sanglard D., Furuya K., Schuetz J.D., and Schuetz E.G. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303 (2002) 323-332
26. Paine M.F., Leung L.Y., Lim H.K., et al. Identification of a novel route of extraction of sirolimus in human small intestine. roles of metabolism and secretion. J Pharmacol Exp Ther 301 (2002) 174-186